EUVIMEDEUVIMED entdecken
Systematische ÜbersichtLeitlinieOpen Access · CC BY 4.0

Guidelines for clinical evaluation of chronic kidney disease in early stages

Yuka Sugawara, Eiichiro Kanda, Takayuki Hamano, Seiji Itano, Hirokazu Okada, Koji Tomori, Yusuke Watanabe, Wataru Asakura, Yoshitaka Isaka, Kunitoshi Iseki, Tomoko Usui, Yusuke Suzuki und 10 weitere

Clinical and Experimental Nephrology · 2024

DOI: 10.1007/s10157-024-02514-6 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical and Experimental Nephrology, 2024. Verfasst von Yuka Sugawara und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. Hauptthemen laut MEDLINE: Glomerular Filtration Rate, Renal Insufficiency, Chronic, Albuminuria. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, The University of Tokyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For the development of pharmaceutical products in kidney field, appropriate surrogate endpoints which can predict long-term prognosis are needed as an alternative to hard endpoints, such as end-stage kidney disease. Though international workshop has proposed estimated glomerular filtration rate (GFR) slope reduction of 0.5–1.0 mL/min/1.73 m /year and 30% decrease in albuminuria/proteinuria as surrogate endpoints in early and advanced chronic kidney disease (CKD), it was not clear whether these are applicable to Japanese patients.

Methods

We analyzed J-CKD-DB and CKD-JAC, Japanese databases/cohorts of CKD patients, and J-DREAMS, a Japanese database of patients with diabetes mellitus to investigate the applicability of eGFR slope and albuminuria/proteinuria to the Japanese population. Systematic review on those endpoints was also conducted including the results of clinical trials published after the above proposal.

Results

Our analysis showed an association between eGFR slope and the risk of end-stage kidney disease. A 30% decrease in albuminuria/proteinuria over 2 years corresponded to a 20% decrease in the risk of end-stage kidney disease patients with baseline UACR ≥ 30 mg/gCre or UPCR ≥ 0.15 g/gCre in the analysis of CKD-JAC, though this analysis was not performed on the other database/cohort. Those results suggested similar trends to those of the systematic review.

Conclusion

The results suggested that eGFR slope and decreased albuminuria/proteinuria may be used as a surrogate endpoint in clinical trials for early CKD (including diabetic kidney disease) in Japanese population, though its validity and cutoff values must be carefully considered based on the latest evidence and other factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerular Filtration RateRenal Insufficiency, ChronicAlbuminuriaHumansJapanBiomarkersKidney Failure, ChronicKidneyDatabases, FactualDisease Progression

Stichwörter der Autor:innen

AlbuminuriaChronic kidney diseaseDiabetic kidney diseaseProteinuriaSurrogate endpointeGFR slope

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
  • Medical Science, Kawasaki Medical School, Okayama, Japan.
  • Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
  • Department of Nephrology and Hypertension, Kawasaki Medical School, Okayama, Japan.
  • Department of Nephrology, Saitama Medical University, Saitama, Japan.
  • Office of New Drug I, Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan.

Förderung

  • Japan Agency for Medical Research and Development
  • The University of Tokyo

Zitieren

APA

Sugawara, Y., Kanda, E., Hamano, T., Itano, S., Okada, H., Tomori, K., Watanabe, Y., Asakura, W., Isaka, Y., Iseki, K., Usui, T., Suzuki, Y., Tanaka, M., Nishimura, R., Fukami, K., Matsushita, K., Wada, J., Watada, H., Ueki, K., …, & Research Working Group for Establishing Guidelines for Clinical Evaluation of Chronic Kidney Disease (2024). Guidelines for clinical evaluation of chronic kidney disease in early stages. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-024-02514-6

Vancouver

Sugawara Y, Kanda E, Hamano T, Itano S, Okada H, Tomori K, et al. Guidelines for clinical evaluation of chronic kidney disease in early stages. Clinical and Experimental Nephrology. 2024. doi:10.1007/s10157-024-02514-6

BibTeX
@article{Sugawara2024,
  author = {Sugawara, Yuka and Kanda, Eiichiro and Hamano, Takayuki and Itano, Seiji and Okada, Hirokazu and Tomori, Koji and Watanabe, Yusuke and Asakura, Wataru and Isaka, Yoshitaka and Iseki, Kunitoshi and Usui, Tomoko and Suzuki, Yusuke and Tanaka, Mototsugu and Nishimura, Rimei and Fukami, Kei and Matsushita, Kunihiro and Wada, Jun and Watada, Hirotaka and Ueki, Kohjiro and Kashihara, Naoki and Nangaku, Masaomi and Research Working Group for Establishing Guidelines for Clinical Evaluation of Chronic Kidney Disease, Research Working Group for Establishing Guidelines for Clinical Evaluation of Chronic Kidney Disease},
  title = {Guidelines for clinical evaluation of chronic kidney disease in early stages},
  journal = {Clinical and Experimental Nephrology},
  year = {2024},
  doi = {10.1007/s10157-024-02514-6}
}
Kostenlos starten →